TY - JOUR T1 - Non-Canonical Targets of HIF1a Drive Cell-Type-Specific Dysfunction JF - bioRxiv DO - 10.1101/2020.04.03.003632 SP - 2020.04.03.003632 AU - Kevin C. Allan AU - Lucille R. Hu AU - Andrew R. Morton AU - Marissa A. Scavuzzo AU - Artur S. Gevorgyan AU - Benjamin L.L. Clayton AU - Ilya R. Bederman AU - Stevephen Hung AU - Cynthia F. Bartels AU - Mayur Madhavan AU - Paul J. Tesar Y1 - 2020/01/01 UR - http://biorxiv.org/content/early/2020/04/16/2020.04.03.003632.abstract N2 - All mammalian cells sense and respond to insufficient oxygen, or hypoxia, through the activity of hypoxia-inducible factors (HIFs), an evolutionarily conserved family of transcriptional regulators that promote oxygen-independent energy metabolism and angiogenesis. While HIF activation is transiently protective for all cells, prolonged HIF activity drives distinct pathological responses in different tissues. How HIF achieves this pleiotropic effect is largely unknown. Here, we demonstrate that non-canonical targets of HIF1a impair the function of oligodendrocyte progenitor cells (OPCs) to generate oligodendrocytes. Beyond the canonical gene targets shared between all cell types, HIF1a also bound to and activated a unique set of targets in OPCs including Ascl2 and Dlx3. Each of these targets, when ectopically expressed, was sufficient to block oligodendrocyte development through suppression of the key oligodendrocyte regulator Sox10. Chemical screening revealed that inhibition of MEK/ERK signaling overcame the HIF1a-mediated block in oligodendrocyte generation by restoring Sox10 expression without impacting canonical HIF1a activity. Collectively this work defines the mechanism by which chronic HIF1a suppresses oligodendrocyte formation. More broadly, we establish that cell-type-specific HIF1a targets, independent of the canonical hypoxia response, perturb cell function and drive disease in chronic hypoxia.Competing Interest StatementP.J.T. is a co-founder and consultant for Convelo therapeutics, which has licensed unrelated patents from Case Western Reserve University. P.J.T and Case Western Reserve University hold equity in Convelo Therapeutics. All other authors have no competing interests. ER -